SCHEMBL273680

SCHEMBL273680

Cc1cccc(/C=N/NC(=O)c2cc(I)ccc2NC(=O)c2cccc(CN3CCC(N4CCCCC4)CC3)c2)c1

nearest known ligand 0.45

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ACKR3 P25106 3/20 0.45
TDP1 Q9NUW8 2/20 0.45
SLC34A2 O95436 5/20 0.41
CYP3A4 P08684 1/20 0.41
MAPT P10636 1/20 0.41
CYP2C9 P11712 1/20 0.41
BACE1 P56817 1/20 0.40
LMNA P02545 1/20 0.40
SLC34A1 Q06495 1/20 0.40
SLC34A3 Q8N130 1/20 0.40
SLC20A1 Q8WUM9 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
SIGMAR1 Q99720 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL268140 1.00 ACKR3 (0.45) ACKR3TDP1SLC34A2CYP3A4MAPT
SCHEMBL265952 0.93 MEN1 (0.42) ACKR3TDP1SLC34A2CYP3A4MAPT
SCHEMBL274290 0.93 MEN1 (0.42) ACKR3TDP1SLC34A2CYP3A4MAPT
SCHEMBL268571 0.93 MEN1 (0.42) TDP1SLC34A2MAPTSLC34A1SLC34A3
SCHEMBL274134 0.93 MEN1 (0.42) TDP1SLC34A2MAPTSLC34A1SLC34A3
SCHEMBL273565 0.92 SLC34A2 (0.48) ACKR3TDP1SLC34A2SLC34A1SLC34A3
SCHEMBL269068 0.92 SLC34A2 (0.48) ACKR3TDP1SLC34A2SLC34A1SLC34A3
SCHEMBL265724 0.92 ACKR3 (0.44) ACKR3TDP1SLC34A2SLC34A1SLC34A3
SCHEMBL273695 0.92 ACKR3 (0.44) ACKR3TDP1SLC34A2SLC34A1SLC34A3
SCHEMBL273677 0.91 SLC34A2 (0.49) ACKR3SLC34A2SLC34A1SLC34A3SLC20A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 ACKR3 809/4885TDP1 4604/4885SLC34A2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.